Business
InspireMD Announces Publication of the C-GUARDIANS Pivotal Trial Manuscript in the Journal of the American College of Cardiology (JACC)
The CGuard® Prime Carotid Stent System demonstrated the lowest 30-day and 1-year primary endpoint major adverse event rates of any pivotal study of carotid stenting (CAS) MIAMI, Jan. 12, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that results from the Company’s C-GUARDIANS pivotal trial have now been published in the Journal of the American College of Car
About this update from Inspiremd Inc.
[{"type":"image","alt":"InspireMD Inc.","displaySize":"","headline":null,"caption":"InspireMD Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":178,"height":24,"url":"https://media.zenfs.com/en/globenewswire.com/291f6cac2fbf0704acd61c88071899d5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xwL0WVQfLKfthWBvqFSgcQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTI4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/291f6cac2fbf0704acd61c88071899d5","width":178,"height":24}},"lazy":false},{"type":"text","content":"The CGuard® Prime Carotid Stent System demonstrated the lowest 30-day and 1-year primary endpoint major adverse event rates of any pivotal study of carotid stenting (CAS)","length":170,"tagName":"p"},{"type":"text","content":"MIAMI, Jan. 12, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that results from the Company’s C-GUARDIANS pivotal trial have now been published in the Journal of the American College of Cardiology (JACC). The data demonstrate the safety and efficacy of carotid artery stenting (CAS) with the Company’s MicroNet™ covered stent in patients with asymptomatic carotid stenosis.","length":513,"tagName":"p"},{"type":"text","content":"As shown at VIVA in late 2023 and LINC in mid-2024, C-GUARDIANS demonstrated low rates of disabling stroke or myocardial infarction (DSMI) through 30 days and low ipsilateral stroke rates through one year, with no unexpected device-related adverse events reported. This pivotal trial showed historically low event rates in patients with obstructive carotid disease at high risk for complications with carotid endarterectomy (CEA). The cohort included 25% symptomatic patients, comparing favorably with similar patients treated with all forms of carotid revascularization in clinical trials. The published study is available here.","length":629,"tagName":"p"},{"type":"text","content":"“The C-GUARDIANS results are exceptional, with a 30-day DSMI rate of just 0.95% and a one-year ipsilateral stroke rate of 1.93%, which are the lowest reported in high-risk patients,” said Dr. Chris Metzger, M.D., Interventional cardiologist and endovascular interventionalist at Ballad Health, and lead investigator of the C-GUARDIANS trial. “What's particularly notew...